TW201740953A - 治療纖維化之方法 - Google Patents

治療纖維化之方法 Download PDF

Info

Publication number
TW201740953A
TW201740953A TW106106688A TW106106688A TW201740953A TW 201740953 A TW201740953 A TW 201740953A TW 106106688 A TW106106688 A TW 106106688A TW 106106688 A TW106106688 A TW 106106688A TW 201740953 A TW201740953 A TW 201740953A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
cancer
fibrosis
group
Prior art date
Application number
TW106106688A
Other languages
English (en)
Chinese (zh)
Inventor
蘿拉 蘇克
法里斯 丹尼爾 瑪梭
托尼 賈塞特 剛薩雷茲
Original Assignee
製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 製藥公司 filed Critical 製藥公司
Publication of TW201740953A publication Critical patent/TW201740953A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B31/00—Disazo and polyazo dyes of the type A->B->C, A->B->C->D, or the like, prepared by diazotising and coupling
    • C09B31/02—Disazo dyes
    • C09B31/12—Disazo dyes from other coupling components "C"
    • C09B31/14—Heterocyclic components
    • C09B31/143—1,2-Diazoles
    • C09B31/147—Pyrazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106106688A 2014-12-03 2015-12-02 治療纖維化之方法 TW201740953A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462086945P 2014-12-03 2014-12-03

Publications (1)

Publication Number Publication Date
TW201740953A true TW201740953A (zh) 2017-12-01

Family

ID=56092404

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106106688A TW201740953A (zh) 2014-12-03 2015-12-02 治療纖維化之方法
TW104140382A TW201625257A (zh) 2014-12-03 2015-12-02 治療纖維化之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104140382A TW201625257A (zh) 2014-12-03 2015-12-02 治療纖維化之方法

Country Status (12)

Country Link
US (2) US9844552B2 (enExample)
EP (1) EP3226864A4 (enExample)
JP (1) JP2017536397A (enExample)
CN (1) CN106999482A (enExample)
AR (1) AR102871A1 (enExample)
AU (1) AU2015358503A1 (enExample)
BR (1) BR112017011897A2 (enExample)
CA (1) CA2968866A1 (enExample)
HK (1) HK1244692A1 (enExample)
MX (1) MX2017007245A (enExample)
TW (2) TW201740953A (enExample)
WO (1) WO2016090021A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CN113694187A (zh) * 2021-07-20 2021-11-26 上海市东方医院（同济大学附属东方医院） 一种用于抑制心肌纤维化的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2011133609A2 (en) * 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
TW202228700A (zh) 2013-12-02 2022-08-01 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
US9982265B2 (en) 2014-03-28 2018-05-29 Board Of Regents, The University Of Texas System Inhibition of Bruton's tyrosine kinase (Btk) in the lung to treat severe lung inflammation and lung injury
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis

Also Published As

Publication number Publication date
CN106999482A (zh) 2017-08-01
HK1244692A1 (zh) 2018-08-17
AR102871A1 (es) 2017-03-29
US10226466B2 (en) 2019-03-12
TW201625257A (zh) 2016-07-16
MX2017007245A (es) 2018-02-16
EP3226864A1 (en) 2017-10-11
WO2016090021A1 (en) 2016-06-09
BR112017011897A2 (pt) 2018-07-03
EP3226864A4 (en) 2018-04-04
US20180153896A1 (en) 2018-06-07
US9844552B2 (en) 2017-12-19
US20160199376A1 (en) 2016-07-14
CA2968866A1 (en) 2016-06-09
AU2015358503A1 (en) 2017-06-08
JP2017536397A (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
US10226466B2 (en) Methods of treating fibrosis
US20160287605A1 (en) Combination therapy
JP2013509444A (ja) がんの治療方法及び治療用組成物
CN103857392A (zh) 用于治疗增生性疾病的2-甲酰胺环氨基尿素衍生物与Hsp90抑制剂的组合
CA3241001A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
US20240122932A1 (en) Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor
US20260053761A1 (en) Use of thyromimetics for the treatment of cancer
JP2012072140A (ja) 異常な細胞増殖を処置する方法
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
JP2023550028A (ja) 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｖｅｇｆ阻害剤を含む方法及び組成物
JP2012512246A5 (enExample)
AU2023372369B2 (en) Combination therapy for treating cancer
JP2025511786A (ja) 筋線維症の治療
TWI698238B (zh) Ｅｚｈ２抑制劑組合治療
EP2928488A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
US20150328197A1 (en) Method and pharmaceutical composition for inhibiting pi3k/akt/mtor signaling pathway
WO2014058785A1 (en) Combination therapy
EA053102B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr